News >

Atezolizumab Monotherapy Improves Survival in Frontline PD-L1-High NSCLC

Jason M. Broderick @jasoncology
Published: Thursday, Sep 12, 2019

Sandra Horning, MD, chief medical officer and head of Global Product Development, Roche

Sandra Horning, MD

Single-agent atezolizumab (Tecentriq) extended overall survival (OS) compared with chemotherapy as a frontline treatment for patients with advanced nonsquamous and squamous non–small cell lung cancer (NSCLC) and high PD-L1 expression, according to topline findings from the phase III IMpower110 trial.

Data from the study available at the time of the approval showed that atezolizumab reduced the risk of death by 26% compared with docetaxel in patients with advanced NSCLC following the failure of platinum-based chemotherapy. The median OS was improved by 4.2 months with the PD-L1 inhibitor versus chemotherapy. The survival benefit with atezolizumab was observed regardless of PD-L1 status or histology.


The international, open-label randomized phase III OAK trial included 1225 patients with locally advanced or metastatic NSCLC—regardless of histology or PD-L1 status—who progressed during or after platinum-containing chemotherapy. Patients were randomized in a 1:1 ratio to 75 mg/m2 of intravenous docetaxel or 1200 mg of intravenous atezolizumab every 3 weeks.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x